Healthcare
Day One Biopharmaceuticals, Inc.(DAWN)
Live Price
Offline$21.53
+0.00% today
Window Change
+232.25%
Window
Jun 23, 2025 โ Apr 24, 2026
- Market Cap
- $2.22B
- Revenue Growth
- +20.6%
- EPS Growth
- -2.0%
- Dividend Yield
- 0.0%
Historical coverage is still expanding
This 1Y daily history view is usable, but not fully loaded yet. Additional bars will appear as backfills continue.
Coverage: 212 bars ยท Jun 23, 2025 โ Apr 24, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Day One Biopharmaceuticals, Inc. (DAWN) is a Healthcare stock with a market cap of $2.22B and listed on NASDAQ. The stock last traded around $21.53 and up 232.3% across the available one-year price window (Jun 23, 2025 โ Apr 24, 2026). Baseline metrics include revenue growth of +20.6%, EPS growth of -2.0%, a dividend yield of 0.0%. What stands out right now is revenue +20.6%, EPS -2.0%, free cash flow -29.6% with operating margin -80.8% and ROIC -28.0%. Valuation already assumes a fairly strong business story at price/sales 14.1. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines DAWN price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+20.6% vs +7.6% peer median
Operating Margin
Below sector median
-80.8% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 5, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at +20.6% and EPS is at -2.0%, with operating margin around -80.8%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +4.9% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Feb 24, 2026 | -17.6% | -9.1% | -16.6% | +77.9% |
2025 Nov 4, 2025 | +31.8% | +25.2% | +41.9% | +13.8% |
2025 Aug 5, 2025 | +17.1% | -15.7% | -10.8% | +8.7% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
DAWN
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
DAWN Max Drawdown
-23.55%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for DAWN and SPY.
Company Overview
Day One Biopharmaceuticals, Inc.
NASDAQ
Day One Biopharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on the identification, development, and commercialization of targeted medicines for life-threatening childhood and adult diseases, particularly cancers, in the United States. Its lead product, OJEMDA (tovorafenib), is an oral, brain-penetrant type II RAF kinase inhibitor approved for pediatric patients with relapsed or refractory BRAF fusion or rearrangement-positive low-grade glioma (pLGG). The company advances tovorafenib in frontline settings through partnerships like with Ipsen for ex-U.S. rights. Day One Biopharmaceuticals, Inc. also develops DAY301, a PTK7-targeted antibody-drug conjugate for advanced solid tumors, and Emi-Le (emiltatug ledadotin), a B7-H4-targeted antibody-drug conjugate for breast, ovarian, endometrial cancers, and adenoid cystic carcinoma. These pipeline assets are in Phase 1 clinical trials. Founded in 2018 and headquartered in the United States, the company employs a 'search & development' strategy led by oncology experts to deliver first- or best-in-class therapies addressing unmet needs in pediatric and adult oncology.
- Leadership
- Dr. Jeremy Bender M.B.A., Ph.D.
- Employees
- 178
- Street Address
- 1800 Sierra Point Parkway, Suite 200
- Mailing
- Brisbane, CA, 94005
- Region
- Brisbane, CA, United States
- Last Updated
- May 12, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 14.1
- Price/Book
- 5.0
Growth
- Revenue
- +20.6%
- EPS
- -2.0%
- Free Cash Flow
- -29.6%
Profitability
- Gross Margin
- 89.1%
- Operating Margin
- -80.8%
- Net Margin
- -67.8%
- ROE
- -23.4%
- ROIC
- -28.0%
Balance Sheet
- Debt/Equity
- 0.01
- Current Ratio
- 8.02
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.